These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

715 related items for PubMed ID: 25630649

  • 41. Long-term surveillance and treatment of subclinical cryptococcosis and nasal colonization by Cryptococcus neoformans and C. gattii species complex in captive koalas (Phascolarctes cinereus).
    Kido N, Makimura K, Kamegaya C, Shindo I, Shibata E, Omiya T, Yamamoto Y.
    Med Mycol; 2012 Apr; 50(3):291-8. PubMed ID: 21859391
    [Abstract] [Full Text] [Related]

  • 42. Fluconazole transport into Candida albicans secretory vesicles by the membrane proteins Cdr1p, Cdr2p, and Mdr1p.
    Basso LR, Gast CE, Mao Y, Wong B.
    Eukaryot Cell; 2010 Jun; 9(6):960-70. PubMed ID: 20348384
    [Abstract] [Full Text] [Related]

  • 43. Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole.
    Khan ZU, Randhawa HS, Chehadeh W, Chowdhary A, Kowshik T, Chandy R.
    Int J Antimicrob Agents; 2009 Jun; 33(6):559-63. PubMed ID: 19195846
    [Abstract] [Full Text] [Related]

  • 44. Enzymatic characterisation of clinical isolates of Cryptococcus neoformans, Cryptococcus gattii and other environmental Cryptococcus spp.
    Chan MY, Tay ST.
    Mycoses; 2010 Jan; 53(1):26-31. PubMed ID: 19389064
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. In vitro susceptibility of Cryptococcus gattii clinical isolates.
    Gomez-Lopez A, Zaragoza O, Dos Anjos Martins M, Melhem MC, Rodriguez-Tudela JL, Cuenca-Estrella M.
    Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.
    Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ.
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2804-15. PubMed ID: 19414582
    [Abstract] [Full Text] [Related]

  • 50. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China.
    Li M, Liao Y, Chen M, Pan W, Weng L.
    Braz J Infect Dis; 2012 Feb; 16(2):175-9. PubMed ID: 22552461
    [Abstract] [Full Text] [Related]

  • 53. Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole.
    Posteraro B, Sanguinetti M, Sanglard D, La Sorda M, Boccia S, Romano L, Morace G, Fadda G.
    Mol Microbiol; 2003 Jan; 47(2):357-71. PubMed ID: 12519188
    [Abstract] [Full Text] [Related]

  • 54. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.
    Nielsen K, Vedula P, Smith KD, Meya DB, Garvey EP, Hoekstra WJ, Schotzinger RJ, Boulware DR.
    Med Mycol; 2017 Jun 01; 55(4):453-456. PubMed ID: 27664991
    [Abstract] [Full Text] [Related]

  • 55. [First description of phenotypic profile and in vitro drug susceptibility of Cryptococcus spp yeast isolated from HIV-positive and HIV-negative patients in State of Mato Grosso].
    Favalessa OC, Ribeiro LC, Tadano T, Fontes CJ, Dias FB, Coelho BP, Hahn RC.
    Rev Soc Bras Med Trop; 2009 Jun 01; 42(6):661-5. PubMed ID: 20209351
    [Abstract] [Full Text] [Related]

  • 56. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H.
    Mycoses; 2006 Jul 01; 49(4):324-30. PubMed ID: 16784448
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List.
    Dao A, Kim HY, Garnham K, Kidd S, Sati H, Perfect J, Sorrell TC, Harrison T, Rickerts V, Gigante V, Alastruey-Izquierdo A, Alffenaar JW, Morrissey CO, Chen SC, Beardsley J.
    Med Mycol; 2024 Jun 27; 62(6):. PubMed ID: 38935902
    [Abstract] [Full Text] [Related]

  • 60. Amino acid substitution in Cryptococcus neoformans lanosterol 14-α-demethylase involved in fluconazole resistance in clinical isolates.
    Bosco-Borgeat ME, Mazza M, Taverna CG, Córdoba S, Murisengo OA, Vivot W, Davel G.
    Rev Argent Microbiol; 2016 Jun 27; 48(2):137-42. PubMed ID: 27311753
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.